Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/09/22
End: 08/12/22
Due: 08/12/23
Phase: N/A
Priority: Normal
Start: 05/01/19
End: 11/13/19
Due: 11/13/20
Phase: N/A
Priority: Normal
Start: 06/17/21
End: 07/19/22
Due: 07/19/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects | NCT05089617 | Youngene Therapeutics Inc., Ltd. | user2@example.com | None | 2022-01-09 | 2022-08-12 | 2023-08-12 | - | - | 2025-07-14 |
| A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 | NCT03953092 | Youngene Therapeutics Inc., Ltd. | user2@example.com | None | 2019-05-01 | 2019-11-13 | 2020-11-13 | - | - | 2025-07-14 |
| A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes | NCT04956263 | Youngene Therapeutics Inc., Ltd. | user2@example.com | None | 2021-06-17 | 2022-07-19 | 2023-07-19 | - | - | 2025-07-14 |